ARA-290 (Cibinetide): A Research Overview
Disclaimer: This content is for laboratory research purposes only. Not for human or animal use.
Table of Contents
Editorial Note
At Optimus Labs, our educational content is developed by reviewing the available scientific literature and aims to provide balanced, evidence-based explanations of peptide research. Unless otherwise stated, the findings discussed in this article are derived primarily from laboratory and animal studies. Research involving humans remains limited for many investigational compounds, and this article should not be interpreted as medical advice or evidence of established clinical efficacy.
What Is ARA-290?
ARA-290 — also known as cibinetide — is an 11-amino-acid synthetic peptide derived from the structure of erythropoietin (EPO).
Think of ARA-290 as a repair signal that has been separated from a side effect. EPO is known for stimulating red blood cell production. But researchers identified that EPO also interacts with a completely different receptor system — one associated with tissue protection and repair. ARA-290 was engineered to interact with only that second system.
The Problem It Was Designed to Solve
To understand why ARA-290 exists, you need to understand the problem with EPO.
EPO is a hormone associated with two very different sets of effects:
| What EPO Is Associated With | Receptor System |
|---|---|
| Stimulation of red blood cell production | Classical EPO receptor (hematopoietic) |
| Tissue protection and repair pathways | Innate repair receptor (non-hematopoietic) |
Think of it like a key that opens two locks. For tissue repair research, the red blood cell effect is an unwanted variable — it changes blood composition and makes it harder to isolate the repair-related observations.
Researchers engineered ARA-290 as a selective key — one designed to interact with only the repair receptor.
The Receptor It Targets
ARA-290 is designed to bind selectively to the innate repair receptor (IRR).
What is the IRR?
The IRR is a receptor complex formed by two proteins joining together:
| Component | Role |
|---|---|
| Erythropoietin receptor (EPOR) | One half of the receptor complex |
| β-common receptor (CD131) | The other half |
When these two proteins combine, they form a receptor expressed on injured tissues and immune cells, associated with anti-inflammatory and tissue repair pathways.
Think of the IRR as an emergency repair switch found on damaged tissue. When activated, it is associated with dampening inflammation and signalling repair.
Important distinction: The IRR is different from the classical EPO receptor. Activating the classical receptor is associated with red blood cell production. Activating the IRR is not. ARA-290 was designed to interact with the IRR selectively.
Proposed Mechanisms
Research has reported several mechanisms through which ARA-290 interacts with the IRR.
Mechanism 1: Reprogramming the Inflammatory Environment
One of the more striking observations in ARA-290 research is its reported association with reprogramming a pro-inflammatory environment toward one of healing and tissue repair.
Think of it as changing the instructions at an injury site. Instead of the immune system continuing to inflame, ARA-290 is studied for its role in shifting the environment toward repair.
Mechanism 2: Inhibition of the NLRP3 Inflammasome
Research has reported that ARA-290 inhibits activation of the NLRP3 inflammasome in Schwann cells after sciatic nerve injury.
What is the NLRP3 inflammasome? It is a protein complex that triggers inflammatory responses. When overactivated, it contributes to tissue damage.
What the research reports:
- ARA-290 was reported to inhibit NLRP3 inflammasome activation in Schwann cells
- This was associated with inhibition of NF-κB phosphorylation
- It was also associated with reduced reactive oxygen species (ROS) production
Think of the NLRP3 inflammasome as a fire alarm that keeps ringing even after the fire is out. ARA-290 is studied for its role in quieting that alarm so repair can proceed.
Mechanism 3: Microglial Polarization
Research in diabetic neuropathy models has reported that ARA-290 promotes M2 microglia polarization.
What does that mean? Microglia are immune cells in the nervous system. They can exist in different states:
| State | What It Is Associated With |
|---|---|
| M1 | Pro-inflammatory responses |
| M2 | Anti-inflammatory responses |
ARA-290 has been reported to promote a shift toward the M2 state in these models.
Think of it as influencing immune cells to shift from attack mode toward repair mode.
Mechanism 4: Tissue Protection Pathways
Research has reported that ARA-290 activates pro-survival pathways in endothelial colony-forming cells (ECFCs) — cells involved in blood vessel repair.
ARA-290 Research Applications
1. Neuropathy Models
ARA-290 has been most extensively studied in preclinical models of neuropathy — conditions involving nerve damage.
Preclinical findings:
- After sciatic nerve injury, ARA-290 was reported to produce rapid and long-term relief of mechanical and cold allodynia in normal mice
- This effect was not observed in animals with a β-common receptor knockout phenotype — confirming that the observed effect depends on the IRR
Note: This is a rodent model finding. It does not establish outcomes in humans.
2. Wound Healing Models
ARA-290 has been studied in diabetic wound healing models.
What the research reports:
- In streptozotocin-induced diabetic rat models, topical ARA-290 was reported to accelerate wound closure
- The treated group was reported to show greater collagen and protein content
- Reduced levels of inflammatory cytokines and lipid peroxidation were reported
- Augmented antioxidant status was reported
Think of it as helping the wound-healing process move past the inflammation stage so that tissue reconstruction can begin.
3. Inflammatory Bowel Disease Models
Cibinetide (ARA-290) has been studied in experimental colitis models.
What the research reports:
- Activation of the IRR was reported to exert anti-inflammatory effects, especially within the myeloid cell population
- It was reported to reduce disease activity and mortality in mice
4. Retinal Research
Research has examined ARA-290’s effects on endothelial colony-forming cells in the ischemic retina.
What the research reports:
- ARA-290 was reported to activate pro-survival pathways in ECFCs
- It was described as not angiogenic in vitro in that study
5. Autoimmune Neuritis Models
ARA-290 has been studied in experimental autoimmune neuritis (EAN) rat models.
What the research reports:
- ARA-290 was reported to alleviate paraparesis, nerve inflammation, and lymphocyte proliferation
- It was reported to suppress inflammatory processes and protect against cytotoxicity
On the Clinical Research
ARA-290 is notable among research peptides in that Phase 2 clinical studies have been conducted — an unusual step for a compound in this category.
What this means: the compound has progressed further into formal clinical investigation than most research peptides. This is a meaningful signal about the level of research interest in the IRR pathway.
What it does not mean: that clinical efficacy has been established. Phase 2 studies are designed to explore whether a compound shows signals of activity and to inform whether larger trials are warranted. ARA-290 is not an approved medicine in any jurisdiction, and no Phase 3 programme has been completed.
Researchers citing this compound should reference the primary literature directly rather than relying on secondary summaries.
What Researchers Should Know
Molecular specifications:
| Property | Specification |
|---|---|
| Full name | ARA-290 / cibinetide |
| Type | Synthetic peptide |
| Length | 11 amino acids |
| Source | Derived from helix-B surface of erythropoietin |
| Sequence | {Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| Molecular weight | ~1,257.31 g/mol |
| Receptor target | Innate repair receptor (EPOR/CD131 heteromer) |
| Regulatory status | Not approved in any jurisdiction; research use only |
Storage:
Lyophilised powder keeps at -20°C long-term, or 2–8°C short-term. Once reconstituted, store at 2–8°C for short-term use, or aliquot and freeze at -80°C. Avoid repeated freeze-thaw cycles.
Frequently Asked Questions
What is ARA-290?
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin, studied for its selective interaction with the innate repair receptor.
How is ARA-290 different from EPO?
EPO is associated with both the classical EPO receptor (red blood cell production) and the innate repair receptor. ARA-290 was designed to interact only with the innate repair receptor.
What is the innate repair receptor?
The IRR is a receptor complex formed by the EPO receptor and the β-common (CD131) receptor. It is expressed on injured tissues and associated with anti-inflammatory and tissue repair pathways.
What has ARA-290 been studied for?
Preclinical models of neuropathy, wound healing, inflammatory bowel disease, retinal injury, and autoimmune neuritis.
Has ARA-290 been studied in humans?
Phase 2 clinical studies have been conducted. However, ARA-290 is not an approved medicine and no Phase 3 programme has been completed.
What is the molecular weight of ARA-290?
Approximately 1,257.31 g/mol.
How should ARA-290 be stored?
Lyophilised powder at -20°C long-term or 2–8°C short-term. Reconstituted solution at 2–8°C short-term, or aliquoted at -80°C.
Key Takeaways
- ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin
- It was designed to selectively interact with the innate repair receptor (IRR) rather than the classical EPO receptor
- The IRR is a heteromer of the EPO receptor and the β-common (CD131) receptor
- It has been studied in preclinical models of neuropathy, wound healing, inflammatory bowel disease, retinal injury, and autoimmune neuritis
- Phase 2 clinical studies have been conducted — an unusual step for a research peptide
- It is not an approved medicine in any jurisdiction
- Storage: lyophilised at -20°C long-term, 2–8°C short-term; reconstituted at 2–8°C short-term or -80°C aliquots
For Research at Optimus Labs
Optimus Labs supplies ARA-290 10mg and other high-purity research peptides for laboratory use, with Certificates of Analysis confirming purity and identity. Orders ship from the UK with tracked delivery.
Explore the rest of the research catalogue for related laboratory compounds, or our overview of the most popular research peptides in the UK.
References
- Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. Targeting the innate repair receptor to treat neuropathy. PAIN Reports. 2016;1(1):e566. – https://journals.lww.com/painrpts/fulltext/10.1097/pr9.0000000000000566
- Liu G, et al. ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury. Eur J Pharmacol. 2025;997:177610. – https://pubmed.ncbi.nlm.nih.gov/40216181/
- Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin. Mol Med. 2015;20:658-66. – https://pubmed.ncbi.nlm.nih.gov/25387363/
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep. 2017. – https://pubmed.ncbi.nlm.nih.gov/29026145/
- Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. Biochim Biophys Acta. 2018. – https://pubmed.ncbi.nlm.nih.gov/29223734/
